Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
10
03
2019
accepted:
26
09
2019
pubmed:
5
10
2019
medline:
28
4
2021
entrez:
5
10
2019
Statut:
ppublish
Résumé
Multiple myeloma is still incurable due to an intrinsic aggressiveness or, more frequently, to the interactions of malignant plasma cells with the bone marrow (BM) microenvironment. Myeloma cells educate BM cells to support neoplastic cell growth, survival, acquisition of drug resistance resulting in disease relapse. Myeloma microenvironment is characterized by Notch signaling hyperactivation due to the increased expression of Notch1 and 2 and the ligands Jagged1 and 2 in tumor cells. Notch activation influences myeloma cell biology and promotes the reprogramming of BM stromal cells. In this work we demonstrate,
Identifiants
pubmed: 31582544
pii: haematol.2019.221077
doi: 10.3324/haematol.2019.221077
pmc: PMC7327642
doi:
Substances chimiques
Jagged-1 Protein
0
Jagged-2 Protein
0
Receptors, Notch
0
Zebrafish Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1925-1936Informations de copyright
Copyright© 2020 Ferrata Storti Foundation.
Références
Leukemia. 2013 Jul;27(7):1558-66
pubmed: 23354012
Blood. 2004 Dec 1;104(12):3697-704
pubmed: 15292061
Oncotarget. 2016 Apr 19;7(16):21713-27
pubmed: 26967055
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
Pathol Res Pract. 2018 Sep;214(9):1388-1394
pubmed: 30098829
Exp Hematol. 2009 Jan;37(1):78-86
pubmed: 19013005
Drugs. 2018 Jan;78(1):19-37
pubmed: 29188449
Blood. 2011 Jul 14;118(2):380-9
pubmed: 21602525
J Steroid Biochem Mol Biol. 2015 Mar;147:24-30
pubmed: 25448748
Ann Hematol. 2010 Nov;89(11):1133-40
pubmed: 20532504
Hum Pathol. 2010 Dec;41(12):1702-10
pubmed: 20800871
Neoplasia. 2019 Jan;21(1):93-105
pubmed: 30529074
J Biol Chem. 2004 Mar 26;279(13):12876-82
pubmed: 14709552
Blood. 2011 Dec 15;118(25):6506-14
pubmed: 21979940
Cancer Lett. 2011 Sep 1;308(1):1-13
pubmed: 21652011
Oncol Lett. 2012 Apr 1;3(4):879-884
pubmed: 22741011
Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20778-83
pubmed: 22143792
Blood. 2007 Nov 15;110(10):3557-60
pubmed: 17690257
Oncotarget. 2015 Sep 29;6(29):26826-40
pubmed: 26308486
Immunol Rev. 2015 Jan;263(1):160-72
pubmed: 25510276
Oncotarget. 2016 Aug 30;7(35):56013-56029
pubmed: 27463014
Target Oncol. 2018 Jun;13(3):257-267
pubmed: 29520705
J Biomed Biotechnol. 2012;2012:157496
pubmed: 23093834
PLoS One. 2017 Nov 3;12(11):e0182640
pubmed: 29099834
Biochem Biophys Res Commun. 2015 Nov 27;467(4):717-22
pubmed: 26494298
Oncotarget. 2014 Nov 15;5(21):10393-406
pubmed: 25257302
Genes Chromosomes Cancer. 2015 Aug;54(8):516-526
pubmed: 26052821
Blood. 2004 May 1;103(9):3511-5
pubmed: 14726396
Front Immunol. 2018 Aug 14;9:1823
pubmed: 30154786
Cancer Lett. 2005 Feb 28;219(1):113-20
pubmed: 15694671
Leukemia. 2013 Apr;27(5):1009-18
pubmed: 23307030
Blood Cancer J. 2012 May;2(5):e73
pubmed: 22829975
Am J Pathol. 2005 Jun;166(6):1817-26
pubmed: 15920166
Cancer Res. 2016 Jan 15;76(2):463-71
pubmed: 26744527
Cancer Res. 2009 May 15;69(10):4380-7
pubmed: 19417136
Int J Biochem Cell Biol. 2015 Sep;66:134-40
pubmed: 26235278
Curr Pharm Des. 2017;23(1):108-134
pubmed: 27719637
Blood. 2016 Jul 14;128(2):249-52
pubmed: 27207793
Leukemia. 2007 May;21(5):1070-8
pubmed: 17315024
Br J Haematol. 2017 Oct;179(1):36-49
pubmed: 28670693
Biochem J. 2013 Apr 1;451(1):123-34
pubmed: 23323858
Front Pharmacol. 2019 Feb 27;10:145
pubmed: 30873026
Biochem Biophys Res Commun. 2012 Nov 30;428(4):518-24
pubmed: 23111325
Development. 1997 Oct;124(20):4133-41
pubmed: 9374409
Toxicol Sci. 2004 Nov;82(1):341-58
pubmed: 15319485
Blood. 2009 Apr 30;113(18):4341-51
pubmed: 19139079
Blood Cancer J. 2017 Dec 15;7(12):650
pubmed: 29242532
Blood. 2008 Feb 15;111(4):2220-9
pubmed: 18039953
Blood. 2004 May 1;103(9):3503-10
pubmed: 14670925
Cancer Res. 2019 Feb 1;79(3):639-649
pubmed: 30563887
Front Oncol. 2014 Sep 25;4:254
pubmed: 25309874